Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: Vir Biotechnology Inc., 3 years.
Vir Biotechnology Inc.
Director
Denali Therapeutics Inc.
Director
Allogene Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 8, 2025 | Vir Biotechnology Inc. | Open-market sale | −10,960 | $12.52 | $137,219 |
| Jan 2, 2025 | Denali Therapeutics Inc. | Open-market sale | −3,080 | $20.91 | $64,403 |
| Nov 7, 2024 | Denali Therapeutics Inc. | Open-market sale | −1,020 | $30.00 | $30,600 |
| Nov 1, 2024 | Denali Therapeutics Inc. | Open-market sale | −3,080 | $27.07 | $83,376 |
| Sep 13, 2024 | Denali Therapeutics Inc. | Open-market sale | −1,020 | $30.00 | $30,600 |
| Sep 3, 2024 | Denali Therapeutics Inc. | Open-market sale | −2,980 | $24.99 | $74,470 |
| Sep 3, 2024 | Denali Therapeutics Inc. | Open-market sale | −100 | $25.37 | $2,537 |
| Jul 1, 2024 | Denali Therapeutics Inc. | Open-market sale | −2,980 | $22.12 | $65,918 |
| Jul 1, 2024 | Denali Therapeutics Inc. | Open-market sale | −100 | $22.86 | $2,286 |
| Jun 5, 2024 | Allogene Therapeutics Inc. | Grant or award | +61,475 | — | — |
| May 31, 2024 | Denali Therapeutics Inc. | Grant or award | +5,967 | — | — |
| May 30, 2024 | Vir Biotechnology Inc. | Grant or award | +8,000 | — | — |
| May 15, 2024 | Denali Therapeutics Inc. | Open-market sale | −1,674 | $20.39 | $34,133 |
| Apr 15, 2024 | Denali Therapeutics Inc. | Open-market sale | −1,666 | $18.29 | $30,471 |
| Mar 15, 2024 | Denali Therapeutics Inc. | Open-market sale | −1,666 | $20.10 | $33,487 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.